Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00) Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/085,117 TRANSMITTAL Filing Date February 27, 2002 **FORM First Named Inventor** David W. MORRIS **Group Art Unit** 1645 (to be used for all correspondence after initial filing) **Examiner Name** To Be Assigned 22 + 162Total Number Of Pages In This Submission Attorney Docket No. 529452000121 Refs. **ENCLOSURES** (check all that apply) Assignment Papers After Allowance Communication to Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Fee Attached Drawing(s) Appeals and Interferences Appeal Communication to Group Amendment / Reply Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition **Proprietary Information** Petition to Convert to a Affidavits/declarations **Status Letter Provisional Application** Power of Attorney, Revocation Other Enclosure(s) (please identify **Extension of Time Request** Change of Correspondence Address below): 1. Form PTO-1449 (9 pages in duplicate) Terminal Disclaimer 2. 162 cited references Return receipt postcard **Express Abandonment Request** Request for Refund Information Disclosure Statement (3 X CD, Number of CD(s)_ pages) Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 Shantanu Basu, Reg. No. 43,318 Individual Name Signature Date April 15, 2003

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on April 15, 2003.

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

TECH CENTER 1600/2900



PATENT Docket No. 529452000121

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231, on April 15, 2003.

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David W. MORRIS and Eric K. ENGELHARD

Serial No.: 10/085,117

Filing Date: February 27, 2002

For: NOVEL COMPOSITIONS AND METHODS FOR CANCER

Examiner: To Be Assigned

Group Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	I nis ii	iformation Disclosure Statement is submitted:
	With t	he application; accordingly, no fee or separate requirements are required.
\boxtimes	Withir	three months of the application filing date or before mailing of a first Office
	Action	on the merits; accordingly, no fee or separate requirements are required.
	After 1	receipt of a first Office Action on the merits but before mailing of a final Office
	Action	or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
	•	is believed to be due.
	After 1	nailing of a final Office Action or Notice of Allowance, but before payment of the
	issue f	ee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmitta
		form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for

any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>529452000121</u>. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 15, 2003

Respectfully submitted,

sy: ____

Shantanu Basu

Registration No. 43,318

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5995 Facsimile: (650) 494-0792

FORM PTO-1449

IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 1 01 3
Docket Number 529452000121	Application Number 10/085,117
Applicant	
David W. MORRI	IS and Eric K. ENGELHARD
Filing Date February 27, 2002	Group Art Unit 1645
Mailing Date April 15, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/18/1979	4,179,337	Davis et al.			
	2.	11/17/1981	4,301,144	Iwashita et al.			
	3.	09/04/1984	4,469,863	Ts'o et al.			
	4.	01/29/1985	4,496,689	Mitra			
	5.	02/03/1987	4,640,835	Shimizu et al.) <u>]</u> [
	6.	06/02/1987	4,670,417	Iwasaki et al.		出	RI A
	7.	12/13/1988	4,791,192	Nakagawa et al.		CEN	E PR
	8.	03/28/1989	4,816,567	Cabilly et al.			2
3	9.	07/23/1991	5,034,506	Summerton et al.		11.7	
	10.	06/23/1992	5,124,246	Urdea et al.		/008	V E 2003
	11.	06/01/1993	5,216,141	Benner		067	J
	12.	08/10/1993	5,235,033	Summerton et al.		0	
	13.	10/25/1994	5,359,100	Urdea et al.			
	14.	01/31/1995	5,386,023	Sanghvi et al.			
	15.	08/29/1995	5,445,934	Fodor et al.			
	16.	08/13/1996	5,545,730	Urdea et al.			
	17.	08/13/1996	5,545,806	Lonberg et al.			
	18.	08/13/1996	5,545,807	Surani et al.			
	19.	10/29/1996	5,569,825	Lonberg et al.			
	20.	11/05/1996	5,571,670	Urdea et al.			
	21.	12/03/1996	5,580,731	Chang et al.			
	22.	01/07/1997	5,591,584	Chang et al.			
	23.	01/14/1997	5,594,117	Urdea et al.			
	24.	01/14/1997	5,594,118	Urdea et al.			
	25.	01/28/1997	5,597,909	Urdea et al.			
	26.	02/11/1997	5,602,240	De Mesmaeker et al.			-

EXAMINER:

DATE CONSIDERED:

APR 2 5 2003 13

INFORMATION DISCLOSURE CITATION

IN AN APPLICATION
(Use several sheets if necessary)

Docket Number 529452000121

Application Number 10/085,117

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date February 27, 2002

Group Art Unit 1645

Mailing Date April 15, 2003

	127	04/20/1007	5 (24 002				
	27.	04/29/1997	5,624,802	Urdea et al.			
	28.	04/29/1997	5,625,126	Lonberg et al.			
	29.	05/27/1997	5,633,425	Lonberg et al.		司	
···	30.	06/03/1997	5,635,352	Urdea et al.		운	→
	31.	06/10/1997	5,637,684	Cook et al.		CEN	APR
	32.	07/01/1997	5,644,048	Yau	·	量	19
	33.	08/26/1997	5,661,016	Lonberg et al.			8 2(
	34.	10/28/1997	5,681,697	Urdea et al.		1600/2900	2003
	35.	10/28/1997	5,681,702	Collins et al.		1990	
	36.	12/23/1997	5,700,637	Southern		1 8	-
	37.	11/28/2000	6,153,441	Appelbaum et al.			 ,

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES N	on VO
	38.	09/11/1987	WO 87/05330	WIPO				
	39.	09/20/1990	WO 90/10448	WIPO				
	40.	04/18/1991	WO 91/04753	WIPO				
	41.	11/11/1993	WO 93/22443	WIPO				
	42.	09/21/1995	WO 95/25116	WIPO				
	43.	12/28/1995	WO 95/35505	WIPO				
	44.	07/31/1997	WO 97/27212	WIPO				
	45.	07/31/1997	WO 97/27213	WIPO				-

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	46.	Allen, J. D. and Berns, A. (1996). "Complementation Tagging of Cooperating Oncogenes in Knockout Mice," Cancer Biology 7:299-306.
	47.	Altschul, S. F. and Gish, W. (1996). "Local Alignment Statistics" <i>In Methods in Enzymology</i> Vol. 266. Academic Press, Inc., pp. 460-480.
	48.	Altschul, S. F. et al. (1990). "Basic Local Alignment Search Tool," J. Mol. Biol. 215:403-410.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa-766647

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000121 Applica

Application Number 10/085,117

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date February 27, 2002

Group Art Unit 1645

Mailing Date April 15, 2003

		Walling Bate riphi 15, 2005
		S w
	49.	Aplin, J. D. and Wriston, Jr., J. C. (1981). "Preparation, Properties, and Applications of Carbay drate Conjugates of Proteins and Lipids," <i>CRC Crit. Rev. Biochem.</i> pp. 259-306.
	50.	Arenberg, D. A. et al. (2001). "The Murine CC Chemokine, 6C-Kine, Inhibits Tumor Growth and Angiogenesis in a Human Lung Cancer SCID Mouse Model," <i>Cancer Immunol. Immunother</i> 49:587-592.
- 11	51. /	Ausubel, F. M. et al., eds. (1992). Short Protocols in Molecular Biology. Greene Publishing Associates and John Wiley & Sons, pp. iii-xviii (Table of Contents Only).
	52.	Bai, J. et al. (1999). "Sequence Comparion of JSRV with Endogenous Proviruses: Envelope Genotypes and a Novel ORF With Similarity to a G-Protein-Coupled Receptor," <i>Virology</i> 258:333-343.
	53. (Beaucage, S. L. and Iyer, R. P. (1993). "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49(10):1925-1963.
	54.	Boener, P. et al. (1991). "Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes," <i>J. Immunol</i> . 147(1):86-95.
	55.	Bolli, M. et al. (1994). "α-Bicyclo-DNA: Synthesis, Characterization, and Pairing Properties of α-DNA-Analogues with Restricted Conformational Flexibility in the Sugar-Phosphate Backbone," Chapter 7 In Carbohydrate Modifications in Antisense Research, ACS Symposium Series 580, Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 100-117.
	56. /	Brill, W. et al. (1989). "Synthesis of Oligodeoxynucleoside Phosphoridithioates via Thioamidites," J. Am Chem soc. 111:2321-2322.
	57.	Brower, V. (1998). "Naked DNA Vaccines Come of Age," Nature Biotechnology 16:1304-1305.
	58.	Carlsson, C. et al. (1996). "Screening for Genetic Mutations," Nature 380:207 (1 page total).
	59.	Cole, S.P.C., et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <i>In</i> Monoclonal Antibodies and Cancer Therapy, Reisfeld, R. A. and Sell, S., ed., Alan R. Liss, New York, p. 77-96 (Includes Table of Contents).
	60	Creighton, T. E., ed. (1983). "Posttranslational Covalent Modifications of Polypeptide Chains," Chapter 2.4 <i>In</i> Proteins: Structure and Molecular Properties. W. H. Freeman & Co., San Francisco pp. 78-86 (Includes Table of Contents).
	61. /	David, G. S. and Reisfeld, R. A. (1974). "Protein Iodination with Solid State Lactoperoxidase," <i>Biochemistry</i> 13(5):1014-1021.
	62. [De Mesmaeker, A. et al. (1994). "Comparison of Rigid and Flexible Backbones in Antisense Oligonucleotides," <i>Bioorganic & Medicinal Chem. Lett.</i> 4(3):395-398.
	63. /	De Mesmaeker, A. et al. (1994). "Novel Backbone Replacements for Oligonucleotides," Chapter 2 In Carbohydrate Modifications in Antisense Research ACS Symposium Series 580. Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 24-39.
	64. [Dempcy, R. O. et al. (1995). "Synthesis of a Thymidyl Pentamer of Deoxyribonucleic Guanidine and Binding Studies with DNA Homopolynucleotides," <i>Proc. Natl Acad. Sci. USA</i> 92:6097-6101.

EXAMINER:

DATE CONSIDERED:

APR 2 5 2003 Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

A 1'

Application Number 10/085,117

Applicant

David W. MORRIS and Eric K. ENGELHAND

Filing Date February 27, 2002

Docket Number 529452000121

Group Art Unit 1645

Mailing Date April 15, 2003

			Maning Date April 13, 2003	
***		/		8
	65.	Desbois, C. et al. (1996). "Exclusion of Tax Oncoprotein," Science 273:951-95		
	66. /	Devereux et al. (1984). "A Comprehen Acid. Res. 12(1):387-395.	sive Set of Sequence Analysis F	Programs for the VAX," Nuc.
-	67.	Doudney, K. et al. (2001). "Comparate Gene for Severe Neural Tube Defects 1q22-q23," Genomics 72(2):180-192.	ive Physical and Transcript Map on Distal Mouse Chromosome 1	os of ~ 1 Mb around <i>looptail</i> , a and Human Chromosome
	68. (Eckstein. F., ed. (1991). Oligonucleoti Press, vii-xvii. (Table of Contents On		Approach, Oxford University
	69. /	Edge, A. S. B. et al. (1981). "Deglyco Acid," Anal. Biochem. 118:131-137.	sylation of Glycoproteins by Tri	fluoromerathneusulfonic
	70.	Egholm, M. (1993). "PNA Hybridizes Crick Hydrogenbonding," <i>Nature</i> 365:	s to Complementary Oligonucleons 566-568.	otides Obeying the Watson-
	71. (Elgholm, M. et al. (1992). "Peptide Nu Peptide Backbone," J. Am. Chem. Soc	ucleic Acids (PNA). Oligonucleo. 114:1895-1897.	otide Analogues with an Achiral
	72. (Erny, K. M. et al. (1996). "Involveme Oncogene 13:2015-2020.	nt of the Tpl-2lcot Oncogene in	MMTV Turmorigenesis,"
	73. (Evan, G. I. et al. (1985). "Isolation of Oncogene Product," <i>Biology</i> 5(12):36		for Human c-myc Proto-
	74.	Fan, L. et al. (2000). "Cutting Edge: I to Trigger Lymphoid Neogenesis," J.	Ectopic Expression of the Chemo Immunol. 164(8):3955-3959.	okine TCA4/SLC is Sufficient
	75. [Feng, D. F. & Doolittle, R. F. (1987) Phylogenetic Trees," J. Mol. Evol. 25:	. "Progressive Sequence Alignm 351-360.	ent as a Prerequisite to Correct
	76.	Field, J. et al. (1988). "Purification of Saccharomyces Cerevisiae by Use of	a RAS-Responsive Adenylyl Cy a Epitope Addition Method," Mo	clase Complex from ol Cell. Biol. 8(5):2159-2165.
	77. (Fishwild, D. M.et al. (1996). "High-A Strain of Minilocus Transgenic Mice,"	vidity Human IgGk Monoclona 'Nature Biotechnology 14:845-8	1 Antibodies from a Novel 851.
	78.	Gallahan, D. and Callahan, R. (1987). New <i>int</i> Locus in Mouse Mammary T 61(1):66-74.	"Mammary Tumorigenesis in I umor Virus (Czech II)-Induced	Feral Mice: Identification of a Mammary Tumors," J. Virol.
	79. (Gao, X. and Jeffs, W. P. (1994). "Unu Duplex," J. Biomolecular NMR 4:17-3		ormacetal Linkage in a DNA
	80. /	Germer, S. et al. (2000). "High-Throu Samples by Kinetic PCR," Genome R	ghput SNP Allele-Frequency Des. 10:258-266.	etermination in Pooled DNA
	81. (Goding, J. W. (1986). "Production of Principles and Practice, Academic President Presi	Monoclonal Antibodies," Chaptess, Inc. 2 nd edition, pp. 59-103.	er 3 <u>In Monoclonal Antibodies:</u>
	_			

EXAMINER:

DATE CONSIDERED:

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000121

Application Number 10/085,117

Applicant

David W. MORRIS and Eric K. ENGELHAR

Filing Date February 27, 2002

Group Art Unit 1645

Mailing Date April 15, 2003

	Mailing Date April 15, 2003
	63 0
82.	Hansen, G. M. et al. (2000). "Genetic Profile of Insertion Mutations in Mouse Leukemias and Lymphomas," Genome Res. 10(2):237-243.
83. /	Heid, C. A et al. (1996). "Real Time Quantitative PCR," Genome Research 6:986-994.
84.	Herdewjn, P. et al. (1994). "Hexopyranosyl-Like Oligonucleotides," Chapter 6 In Carbohydrate Modifications in Antisense Research ACS Symposium Series 580. Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 80-99.
85.	Higgins, D. G. and Sharp, P. M. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," <i>CABIOS</i> 5(2):151-153.
86.	Hoogenboom, H. R. and Winter, G. (1991). "By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro," J. Mol. Biol. 227:381
87.	Hopp, T. P. et al. (1988). "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> 6:1204-1210.
88. /	Horn, T. et al. (1996). "Oligonucleotides with Alternating Anionic and Cationic Phosphoramidate Linkages: Synthesis and Hybridization of Stereo-Uniform Isomers," <i>Tetrahedron Letters</i> 37(6):743-746.
89. (Hwang, H. C. et al. (2002). "Identification of Oncognes Collaborating with p27 ^{Kip1} Loss by Insertional Mutagenesis and High-Throughput Insertion Site Analysis," <i>Proc. Natl Acad. Sci. USA</i> 99(17):11293-11298 (Includes supporting information).
90. /	Jenkins, G. N. and Turner, N. J. (1995). "The Biosynthesis of Carbocyclic Nucleosides," <i>Chem. Soc. Rev.</i> pp. 169-176.
91. /	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.
92	Jonkers, J. and Berns, A. (1996). "Retroviral Insertional Mutagenesis as a Strategy to Identify Cancel Genes," <i>Biochim. Biophys. Acta</i> 1287:29-57.
93. /	Joosten, M. et al. (2000). "Phenotyping of Evi 1, Evi 11/Cb2, and Evi 12 Transformed Leukemias Isolated from a Novel Panel of Cas-Br-M Murine Leukemia Virus-Infected Mice," J. Virology 268:308-318.
94. /	Jung, M. P. et al. (1994). "Hybridization of alternating Cationic/Anionic Oligonucleotides to RNA Segments," <i>Nucleosides & Nucleotides</i> 13(6&7):1597-1605.
95. (Karlin, S. et al. (1993). "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," <i>Proc. Natl Acad. Sci. USA</i> 90:5873-5787.
96. /	Köhler, G. and Milstein, C. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.
97.	Kohno, T. et al. (2000). "Identification of Genes Associated with the Progression of Adult T-Cell Leukemia (ATL)," <i>Jpn J. Cancer Res.</i> 91:1103-1110.

EXAMINER:

DATE CONSIDERED:

APR 2 5 2003 Application Number 10/085,117 Docket Number 529452000121 Form PTO **Applicant**

TION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

David W. MORRIS and Eric K. ENGELHAR

Group Art Unit 1645 Filing Date February 27, 2002

Mailing Date April 15, 2003

	S S
98.	Lee, F. S. et al. (1995). "Insertional Mutagenesis Identifies a Member of the Wnt Gene Family a Candidate Oncogene in the Mammary Eptithelium of int-2l/Fgf-3 Transgenic Mice," Proc. Nat. Acad. Sci. USA 92:2268-2272.
99. /	Lee, S. Wong et al. (1999). "Cloning of Mouse Sepiapterin Reductase Gene and Characterization of its Promoter Region," <i>Biochimica and Biophysica Acta</i> 1445(1):165-171.
100.	Letsinger, R. L. et al. (1986). "Effects of Pendant Group at Phosphorus on Binding Properties of d-ApA Analogues," <i>Nucl. Acids. Res</i> 14:3487-3499.
101./	Letsinger, R. L. et al. (1988). "Cationic Oligonucleotides," J. Am. Chem. Soc. 110:4470-4471.
102./	Letsinger, R.L. and Mungall, W. S. (1970). "Phosphoramidate Analogs of Oligonucleotides," J. Org. Chem 35(11):3800-3803.
103./	Li, J. et al. (1999). "Leukaemia Disease Genes: Large-Scale Cloning and Pathway Predictions," Nature Genetics 23:348-353.
104.	Lockhart, D. J. et al. (1996). "Expression Monitoring by Hybridization High-Density Oligonucleotide Arrays," <i>Nature Biotechnology</i> , 14:1675-1680.
105.	Lonberg, N. and Huszar, D. (1995). "Human Antibodies from Transgenic Mice," <i>Intern. Rev. Immunol.</i> 13:65-93.
106.	Longberg, N. et al. (1994). "Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications," <i>Nature</i> 368:856-859.
107. (Lund, A. H. et al. (2002). "Genome-Wide Retroviral Insertional Tagging of Genes Involved in Cancer in Cdkn2a-Deficient Mice," <i>Nature Genetics Advance online Publication</i> pp. 1-6.
108.	Lutz-Freyermuth, C. et al. (1990). "Quantitative Determination That One of Two Potential RNA-Binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-Loop II of U1 RNA," <i>Proc. Natl Acad. Sci. USA</i> 87:6393-6397.
109.	MacArthur, C. A. et al. (1995). "Fgf-8, Activated by Proviral Insertion, Cooperates with the Wnt-1 Transgene in Murine Mammary Tumorigenesis," J. Virol. 69(4):2501-2507.
110.	Maddry, J. A. et al. (1994). "Synthesis of Nonionic Oligonucleotide Analogues," Chapter 3 In Carbohydrate Modifications in Antisense Research. ACS Symposium Series 580 Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 40-51.
111. /	Mag, M. et al. (1991). "Synthesis and Selective Cleavage of an Oligodeoynucleotide Containing a Bridged Internucleotide 5'-Phosphorotiate Linkage," <i>Nucleic Acids Res.</i> 19:1437-1441.
112.	Marchetti, A. et al. (1995). "Int-6, a Highly Conserved, Widely Expressed Gene, is Mutated by Mouse Mammary Tumor Virus in Mammary Preneoplasia," J. Virol. 69:1932-1938.
113./	Marks, J. D. et al. (1991). "By-Passing Immunization, Human Antibodies from V-Gene Libraries Displayed on Phage," J. Mol. Biol. 222:581-597.
114.	Marks, J. D. et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> 10:779-783.

EXAMINER:

DATE CONSIDERED:

APR 2 5 2003 Form PTO-1448

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

David W. MORRIS and Eric K. ENGEL

Filing Date February 27, 2002

Docket Number 529452000121

Group Art Unit 16

Application Number 10/085,117

	Mailing Date April 15, 2003
115. <	Martin, G. A. et al. (1992). "GAP Domains Responsible for Ras p21-Dependent Inhibition Muscarinic Atrial K+ Channel Currents," Science 255:192-194.
116. /	Meier, C. et al. (1992). "Peptide Nucleic Acids (PNAs) Unusual Properties of Nonionic Oligonucleotide Analogues," Angew Chem. Int. ed. Engl. 31(8):1008-1010.
117.	Mikkers ,H. et al. (2002). "High-Throughput Retroviral Tagging to Identify Components of Specific Signaling Pathways in Cancer," <i>Nature Genetics Advance Online Publication</i> , pp. 1-7.
118. (Moore, A. S. (2001). "The Role of Chemoattraction in Cancer Metastases," BioEssays 23:674-676.
119.	Morris, D. W. et al. (1986). "Transfer, by Selective Breeding, of the Pathogenic <i>Mtv-2</i> Endogenous Provirus from the GR strain to a Wild Mouse Line Free of Endogenous and Exogenous Mouse Mammary Tumor Virus," <i>J. Virol.</i> 58(2):247-252.
120.	Morris, D. W. et al. (1990). "Insertion Mutation of the <i>Int-1</i> and <i>Int-2</i> Loci by Mouse Mammary Tumor Virus in Premalignant and Malignant Neoplasms from the GR Mouse Strain," <i>J. Virol</i> . 64(4):1794-1802.
121.	Morrison, S. L. (1994). "Success in Specification," Nature 368:812-813.
122.	Müller, A. et al. (2001). "Involvement of Chemokine Receptors in Breast Cancer Metastasis," Natur 410:50-56.
123.	Needleman, S. B. and Wunsch, C. D. (1970). "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," J. Mol. Biol. 48:443-453.
124.	Neuberger, M. (1996). "Generating High-Avidity Human Mabs in Mice," <i>Nature Biotechnology</i> 14:826 (1 page total).
125. /	Nusse, R. and Varmus, H. E. (1982). "Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome," <i>Cell</i> 31:99-109.
126. /	Nygren, H. (1982). "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents," <i>Histochem. and Cytochem.</i> 30(5):407-412.
127. /	Paborsky, L. R. et al. (1990). "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen," <i>Protein Engineering</i> 3(6):547-553.
128.	Pain, D. and Surolia, A. (1981). "Preparation of Protein A-Peroxidase Monoconjugate Using A.Heterobifunctional Reagent, and its Use in Enzyme Immunoassays," J. Immunol. Meth. 40:219-23
129.	Palmarini, M. et al. (1999). "Jaagsiekte Sheep Retrovirus is Necessary and Sufficient to Induce a Contagious Lung Cancer in Sheep," J. Virol. 73(8):6964-6972.
130.	Pauwels, R. et al. (1986). "Biological Activity of New 2-5A Analogues," Chemica Scripta 26:141-145.
131.	Pearson, W. R. and Lipman, D. J. (1988). "Improved Tools for Biological Sequence Comparison," <i>Proc. Natl Acad. Sci. USA</i> 85:2444-2448.

EXAMINER:

DATE CONSIDERED:

APR 2 5 2003 Form PTO-1449

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000121

Application Number 10/085,117

Applicant

David W. MORRIS and Eric K. ENGELHAD

Filing Date February 27, 2002

Group Art Unit 1643

			Mailing Date April 15, 2003	分	2003			
	132./	Peters, G. et al. (1983). "Tumorigeness Region for Provirus Integration in Man	is by Mouse Mammary Turmor Virus: Eventure Turmors," Cell 33:369-377.	idence for a	ammon .			
	133. /	Peters, G. et al. (1989). "The Mouse Homolog of the <i>Hst/k-FGF</i> Gene is Adjacent to <i>int-2</i> and is Activated by Proviral Insertion in Some Virally Induced Mammary Tumors," <i>Proc. Natl. Acad. Sci. USA</i> 86:5678-5682.						
	134.<	Pierce (1994). "Cross-Linking," Pierce	ce Catalog and Handbook pp. 155-200.	,				
	135.	Presta, L. G. (1992). "Antibody Engir	neering", Current Opinion in Structural Bi	iology 2:593-5	596.			
	136. [Rawls, R. L. (1997). "Optimistic Abo	ut Antisense," C & E News pp. 35-40.					
	137. /	Riechmann, L. et al. (1988). "Reshapi	ing Human Antibodies for Therapy," Natu	ire 332:323-32	27.			
	138.	Roelink, H. et al. (1990). "Wnt-3, a Ge is Homologous to int-1/Wnt-1 and is N Proc. Natl. Acad. Sci USA 87:4519-45	ene Activated by Proviral Insertion in Mou Normally Expressed in Mouse Embryos and 23.	ise Mammary nd Adult Brain	Tumors n,"			
	139. (Sambrook, J. et al., eds. (1989). Mole Spring Harbor Laboraroty Press. pp.x	ecular Cloning, a Laboratory Manual, Seci- i-xxxviii. (Table of Contents Only).	ond Edition.	Cold			
	140./	Scopes, R. K.,ed. (1982). <u>Protein Purification: Principles and Practice.</u> Springer-Verlag, New York, Heidelberg, Berlin, pp. xi-xiii.						
	141. /	Shiramizu, B. et al. (1994). "Identification of a Common Clonal Human Immunodeficiency Virus Integration Site in Human Immunodeficiency Virus-Associated Lymphomas," <i>Cancer Res.</i> 54:2069-2072.						
	142. [Smith, T. F. and Waterman, M. S. (19489.	981). "Comparison of Biosequences," Adv	. Appl. Math.	2:482-			
	143.	Sojar, H. T. and Bahl, O. P. (1987). "A Archives of Biochemistry and Biophys	A Chemical Method for the Deglycosylation ics 259(1):52-57.	on of Proteins	"			
	144. (fication and Sequence Analysis of DNA From Merase Chain Reaction Method," Journa		rated			
	145.	Sorensen, A. B. et al. (1996). "Sequer Induced by the Murine Retrovirus SL3	nce Tags of Provirus Integration Sites in E3-3," J. Virology 70(6):4063-4070.)NAs of Tume	ors			
	146.		Common Integration Site in SL3-3-Induction-Oncogene with Homology to the Septin		" J.			
	147.	Sprinzl, M. et al. (1977). "Enzymatic ItRNA," Eur. J. Biochem 81:579-589.	Incorporation of ATP and CTP Analogues	Into the 3' E	nd of			
	148.	Stein, C. A. and Cohen, J. S. (1988). Review," <i>Cancer Res</i> . 48:2659-2668.	"Oligodeoxynucleotides as Inhibitors of C	Gene Expressi	ion: A			
- 1	149. <i>[</i>	Sternsdorf, T. et al. (1997). "Nuclear I	Dots: Actors on Many Stages," Immunobio	ology 198:307	7-331.			

EXAMINER:

DATE CONSIDERED:

Form PTO-1449

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000121	Application Number 10/085,117

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date February 27, 2002 Group Art Unit 1645

Mailing Date April 15, 2003

150.	Suzuki, T. et al. (2002). "New Genes Involved in Cancer Identified by Retroviral Tagging," Nature Genetics Advance Online Publication pp. 1-9.
151. /	Suzuki, T. et al. (2002). Retroviral Tagging in the Post-Genome Era Identifies New Genes Involved in Cancer. (1 page total)
152.	Thotakura, N. R. and Bahl, O. P. (1987). "Enzymathic Deglycosylation of Glycoproteins," <i>In</i> Methods in Enzymology Academic Press, Inc., Vol. 138 pp. 350-359.
153.	Tijssen (1993). "Overview of Principles of Hybridization and the strategy of nucleic acid assays," Chapter 2 <i>In</i> Laboratory Techniques in Biochemistry and Molecular Biology, Hybridization with Nucleic Acid Probes Volume 24 Van der Vliet, P. C., ed. Elsevier, Amsterdam, London, New York, and Tokyo, Volume 24 pp. 20-78.
154.	Van der Krol, A. R et al. (1988). "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," <i>Biotechniques</i> 6(10):958-976.
155.	Varmus, H. E. (1983). "Using Retroviruses as Insertional Mutagens to Identify Cellular Oncogenes," In Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential. Alan R. Liss, Inc., New York. pp. 23-35.
156.	Vaughn, J. et al. (2000). "Genomic Structure and Expression of Human KCNJ9 (Kir3.3/GIRK3)," Biochem. Biophys. Res. Commun 274(2):302-309.
157. /	Verhoeyen, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science 239:1534-1536.
158. /	von Kiedrowski, G. et al. (1991). "Parabolic Growth of a Self-Replicating Hexadeoxynucleotide Bearing a 3'-5'-Phosphoamidate Linkage," <i>Angew. Chem. Int. Ed. Engl</i> 30(4):423-426.
159. /	Washington University. (2002). "Washington University BLASTArchives" located at http://blast.wustl.edu visited on December 15, 2002, three pages
160. /	Wolford, J. K. (2001). "Analysis of Linkage Disequilibrium Between Polymorphisms in the KCNJ9 Gene with Type 2 Diabetes Mellitus in Pima Indians," Mol. Genet. Metab. 73(1):97-103.
161./	Zhang, W-X and Yang, S. Y. (2000). "Cloning and Characterization of a New Member of the T-Box Gene Family," <i>Genomics</i> 70(1):41-48.
162./	Zlokarnik, G. et al. (1998). "Quantitation of Transcription and Clonal Selection of Single Living Cells with β -Lactamase as Reporter," <i>Science</i> 279:84-88.

TECH CENTER 28 2003

EXAMINER:

DATE CONSIDERED: